EGFR and adenocarcinoma: It has been demonstrated that inhibition of the epidermal growth receptor (EGFR) pathway with tyrosine kinase inhibitors (TKIs) provides effective treatment and improved tolerability for non-small-cell lung cancers, especially for a subset of female patients of East Asian origin who are never smokers and have an adenocarcinoma histology, and who have high prevalence of sensitive activating EGFR mutations (deletion in exon 19 or point mutation of L858 in exon 21) [10].